These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12388653)

  • 1. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.
    Comer SD; Collins ED
    J Pharmacol Exp Ther; 2002 Nov; 303(2):695-703. PubMed ID: 12388653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous buprenorphine self-administration by detoxified heroin abusers.
    Comer SD; Collins ED; Fischman MW
    J Pharmacol Exp Ther; 2002 Apr; 301(1):266-76. PubMed ID: 11907183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.
    Comer SD; Sullivan MA; Walker EA
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1320-30. PubMed ID: 16144974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.
    Jones JD; Manubay JM; Mogali S; Metz VE; Madera G; Martinez S; Mumtaz M; Comer SD
    Drug Alcohol Depend; 2017 Oct; 179():362-369. PubMed ID: 28844013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
    Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
    Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.
    Jones JD; Madera G; Comer SD
    Pharmacol Biochem Behav; 2014 Jul; 122():299-306. PubMed ID: 24793093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.
    Comer SD; Collins ED; Fischman MW
    Psychopharmacology (Berl); 2001 Feb; 154(1):28-37. PubMed ID: 11292003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.
    Comer SD; Walker EA; Collins ED
    Psychopharmacology (Berl); 2005 Oct; 181(4):664-75. PubMed ID: 16025322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.
    Jones JD; Sullivan MA; Vosburg SK; Manubay JM; Mogali S; Metz V; Comer SD
    Addict Biol; 2015 Jul; 20(4):784-98. PubMed ID: 25060839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.
    Comer SD; Sullivan MA; Whittington RA; Vosburg SK; Kowalczyk WJ
    Neuropsychopharmacology; 2008 Apr; 33(5):1179-91. PubMed ID: 17581533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance.
    Greenwald MK; Johanson CE; Schuster CR
    Drug Alcohol Depend; 1999 Oct; 56(3):191-203. PubMed ID: 10529021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
    Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
    J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an alternative reinforcer on intravenous heroin self-administration by humans.
    Comer SD; Collins ED; Wilson ST; Donovan MR; Foltin RW; Fischman MW
    Eur J Pharmacol; 1998 Mar; 345(1):13-26. PubMed ID: 9593589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients.
    Vicknasingam B; Dazali MN; Singh D; Schottenfeld RS; Chawarski MC
    Drug Alcohol Depend; 2015 Jul; 152():164-9. PubMed ID: 25935736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
    Rothman RB; Gorelick DA; Heishman SJ; Eichmiller PR; Hill BH; Norbeck J; Liberto JG
    J Subst Abuse Treat; 2000 Apr; 18(3):277-81. PubMed ID: 10742642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
    Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
    J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.